- Home
- PRPO
PRPO
Precipio Inc.
as of 12-11-2025 1:04pm EST
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | OMAHA |
| Market Cap: | 32.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 14.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.90 - $28.50 | Next Earning Date: | 11-14-2025 |
| Revenue: | $22,800,000 | Revenue Growth: | 30.95% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Precipio Inc. (PRPO)
Chief Operating Officer
Avg Cost/Share
$19.50
Shares
25
Total Value
$487.50
Owned After
715
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sabet Ahmed Zaki | PRPO | Chief Operating Officer | Oct 1, 2025 | Buy | $19.50 | 25 | $487.50 | 715 |
Compare PRPO vs Leading Stocks
See how PRPO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PRPO Precipio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.